Insider Ownership
OtherBuck Elizabeth
CHIEF SCIENTIFIC OFFICER
CEOVelleca Mark A.
PRESIDENT & CEO
OtherHatzis-Schoch Brent
SEE REMARKS
OtherYurasov Sergey
CHIEF MEDICAL OFFICER
Transactions
50 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|
| 2025-03-19 | BIOTECH GROWTH N V | - | Sell | 5,784,292 | $2.07 | $11,997,749.13 | -14.2% | → |
| 2024-08-28 | Versant Venture Capital VI, L.P. | - | Sell | 221,600 | $6.32 | $1,400,556.32 | -5.6% | → |
| 2023-10-17 | BIOTECH GROWTH N V | - | Buy | 400,000 | $2.34 | $934,080.00 | +4.9% | → |
| 2023-07-05 | RA CAPITAL MANAGEMENT, L.P. | - | Buy | 935,850 | $5.00 | $4,679,250.00 | +41.1% | → |
| 2023-07-05 | Behbahani Ali | - | Buy | 1,000,000 | $5.00 | $5,000,000.00 | +29.0% | → |
| 2023-06-30 | BIOTECH GROWTH N V | - | Buy | 1,000,000 | $5.00 | $5,000,000.00 | +14.0% | → |
| 2023-06-27 | Epstein David M. | SEE REMARKS | Sell | 25,000 | $6.70 | $167,500.00 | -3.6% | → |
| 2023-06-27 | BIOTECH GROWTH N V | - | Buy | 1,740,000 | $5.49 | $9,555,036.00 | +32.4% | → |
| 2022-12-22 | Ni Fang | SEE REMARKS | Buy | 56,363 | $1.28 | $72,365.55 | +35.7% | → |
| 2022-10-31 | BIOTECH GROWTH N V | - | Buy | 99,801 | $2.25 | $224,911.53 | +1.9% | → |
| 2022-10-28 | BIOTECH GROWTH N V | - | Buy | 364,652 | $2.02 | $736,185.98 | +3.6% | → |
| 2022-10-21 | BIOTECH GROWTH N V | - | Buy | 87,850 | $1.51 | $132,750.14 | +1.8% | → |
| 2022-10-20 | BIOTECH GROWTH N V | - | Buy | 131,423 | $1.36 | $179,120.05 | +1.4% | → |
| 2022-06-29 | Ni Fang | SEE REMARKS | Buy | 25,000 | $2.44 | $61,017.50 | +56.8% | → |
| 2022-04-28 | BIOTECH GROWTH N V | - | Buy | 405,711 | $2.61 | $1,057,347.69 | +4.6% | → |
| 2022-04-19 | BIOTECH GROWTH N V | - | Buy | 300,000 | $3.27 | $980,580.00 | +3.7% | → |
| 2022-04-13 | BIOTECH GROWTH N V | - | Buy | 252,556 | $3.48 | $879,817.22 | +3.3% | → |
| 2021-05-12 | Hatzis-Schoch Brent | See Remarks | Sale+OE | 4,078 | $27.42 | $111,804.83 | -12.5% | → |
| 2021-05-03 | Roberts Christopher D. | Chief Scientific Officer | Sale+OE | 2,500 | $26.64 | $66,602.25 | -43.9% | → |
| 2021-04-12 | Hatzis-Schoch Brent | See Remarks | Sale+OE | 4,078 | $25.00 | $101,950.00 | -32.7% | → |
| 2021-04-05 | Roberts Christopher D. | Chief Scientific Officer | Sale+OE | 2,500 | $25.54 | $63,847.50 | -43.9% | → |
| 2021-03-12 | Hatzis-Schoch Brent | See Remarks | Sale+OE | 4,078 | $26.36 | $107,493.23 | -32.7% | → |
| 2021-03-03 | Roberts Christopher D. | Chief Scientific Officer | Sale+OE | 2,500 | $26.10 | $65,261.83 | -25.6% | → |
| 2021-02-12 | Hatzis-Schoch Brent | See Remarks | Sale+OE | 4,078 | $27.23 | $111,024.94 | -19.2% | → |
| 2021-02-03 | Roberts Christopher D. | Chief Scientific Officer | Sale+OE | 2,500 | $25.35 | $63,375.00 | -43.9% | → |
| 2021-01-12 | Hatzis-Schoch Brent | See Remarks | Sale+OE | 11,578 | $34.03 | $394,040.62 | -11.3% | → |
| 2021-01-08 | Leggett Thomas | Chief Financial Officer | Sale+OE | 3,000 | $33.94 | $101,820.00 | -100% | → |
| 2021-01-04 | Epstein David M. | See Remarks | Sale+OE | 9,985 | $30.99 | $309,430.16 | -1.4% | → |
| 2021-01-04 | Roberts Christopher D. | Chief Scientific Officer | Sale+OE | 537 | $31.78 | $17,064.52 | -14.4% | → |